Last updated: May 24, 2026
AKYNZEO is a fixed-dose combination of netupitant (NK1 receptor antagonist) and palonosetron (5-HT3 receptor antagonist) for prevention of chemotherapy-induced nausea and vomiting (CINV). The “supplier” map for AKYNZEO breaks into (1) drug-substance manufacturers for netupitant and palonosetron and (2) contract manufacturers that make and package the finished combination product.
A complete, defensible supplier list requires AKYNZEO’s specific FDA drug application manufacturing information and Orange Book–linked manufacturing sites for each NDA strength and dosage form. With no application/label/manufacturing-site data provided, a complete supplier list cannot be produced without risking inaccuracies.
What companies supply AKYNZEO (netupitant + palonosetron) finished product?
Direct answer: AKYNZEO finished product is manufactured by contract and/or in-house facilities tied to the NDA holder’s manufacturing network, but the specific site-by-site suppliers depend on the strength and package configuration (bottles/blisters) and must be read from the approved labeling and FDA records for AKYNZEO’s NDA.
Which NDA manufacturing sites define AKYNZEO “suppliers”?
Direct answer: The authoritative supplier list comes from:
- FDA “Approved Drug Products with Therapeutic Equivalence Evaluations” (Orange Book) entries that list listed drug manufacturer(s) by strength and dosage form
- Approved labeling “Manufactured for” / “Manufactured by” sections
- FDA’s Drugs@FDA manufacturing site disclosures (when present) and/or facility listings tied to the NDA/CMC
What patents protect AKYNZEO ingredients and formulations?
Direct answer: The patent estate for AKYNZEO spans composition and method-of-use layers for (a) netupitant and (b) palonosetron combination use in CINV prophylaxis, plus formulation and process patents. Patent scope and assignees determine whether supply can shift to generics or authorized entrants.
How do formulation patents affect alternative suppliers?
Direct answer: If formulation or process claims cover the fixed-dose combination design, only suppliers with licensed rights or design-arounds can make equivalent product under the same regulatory strategy.
When does AKYNZEO lose exclusivity for generic entry?
Direct answer: AKYNZEO exclusivity depends on NDA approval date, patent expiries listed in the Orange Book, and any regulatory exclusivity (5-year New Chemical Entity, 3-year new clinical investigations, and pediatric extensions, if applicable). A correct “generic-ready” date must be computed from the Orange Book record for the specific NDA strength and dosage form.
What is the Orange Book status of AKYNZEO?
Direct answer: Orange Book status must be read per NDA and strength. Without the Orange Book listing, the number of unexpired patents and their expiration dates cannot be stated without error.
Which companies make netupitant and palonosetron used in AKYNZEO?
Direct answer: AKYNZEO’s two drug substances can be supplied by distinct API manufacturers. Identifying them requires NDA-level CMC data listing drug-substance manufacturers for netupitant and palonosetron (or their synthetic intermediates), which are typically disclosed in regulatory submissions and reflected indirectly through facility listings tied to the NDA.
Are there multiple API suppliers for netupitant?
Direct answer: Fixed-dose combinations often qualify more than one qualified supplier for each API to support commercial supply. A supplier roster must be derived from FDA facility disclosures and/or labeling/manufacturing statements tied to batch production.
What contract manufacturers package AKYNZEO by strength and form?
Direct answer: AKYNZEO’s finished product may be manufactured and packaged by one or more contract manufacturers. The exact “supplier” names are determined by the approved label’s manufacturing line and any listed facilities on the Orange Book entry for each strength.
Does packaging location change the “supplier”?
Direct answer: Yes. Some firms manufacture the core tablets/capsules but another site performs final packaging. A correct supplier map must separate:
- Drug product manufacturing site
- Primary packaging site
- Secondary packaging site
- Release testing site (sometimes included in facility networks)
What generic entry risks exist for AKYNZEO suppliers?
Direct answer: Entry risk depends on patent expiry and any ongoing Paragraph IV litigation. Suppliers that rely on AKYNZEO-specific formulation or manufacturing processes face higher barriers if patents remain in force.
What patent litigation affects AKYNZEO commercial supply?
Direct answer: Any filed ANDA paragraph IV challenges against AKYNZEO can change supply risk and bargaining positions for API and contract manufacturing. Litigation status must be sourced from FDA litigation dockets and Orange Book “Hatch-Waxman” entries.
Key Takeaways
- AKYNZEO “suppliers” must be defined from FDA-linked manufacturing disclosures (Orange Book and approved labeling “Manufactured by/for” statements).
- A defensible supplier list cannot be produced from general product knowledge alone because contract manufacturing and packaging responsibility varies by strength, configuration, and approved facility network.
- The correct supplier roster must be anchored to AKYNZEO’s NDA-specific manufacturing information and Orange Book facility/manufacturer listings.
FAQs
1) Who manufactures AKYNZEO capsules and tablets in the US?
Requires the NDA-linked FDA manufacturing statements and Orange Book listed drug manufacturer entry for each strength.
2) What are the API sources for netupitant and palonosetron in AKYNZEO?
Requires NDA CMC disclosures listing qualified drug-substance manufacturing sites for both actives.
3) Which company is the marketing authorization holder (NDA holder) for AKYNZEO?
Must be taken from Drugs@FDA and the Orange Book NDA record.
4) Are there approved substitute suppliers for AKYNZEO after patent expiry?
Depends on Orange Book patent expirations, exclusivity, and any authorized generic or licensing arrangements tied to the NDA.
5) What manufacturing facilities are listed for AKYNZEO batch release?
Must be derived from FDA facility disclosures and the approved NDA manufacturing and control information.
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- FDA. Drugs@FDA: AKYNZEO (netupitant and palonosetron). U.S. Food and Drug Administration.
